RxDoctor Payments DataLook up a doctor →

Ricky Henderson, MD

Cardiovascular Disease · Anderson, SCNPI 1487667523

Payments from drug & device makers

$95,558in general payments, 2019–2025

Across 895 payments — averaging $106.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$41K
  • Medtronic$30K
  • Biotronik Inc.$11K
  • Abbott$5K
  • Biosense Webster, Inc.$3K
  • Medical Device Business Services, Inc.$771
  • plus $5K from 27 others

What the payments were for

  • Consulting fees$15,31429%
  • Speaking & faculty fees$5,10010%
  • Travel & lodging$11,04921%
  • Food & beverage$20,63940%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$95,558 in reported general payments places this provider in the 90th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$424,108
Medicare patients
802
Services billed
3,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban306$291,988
Droxidopa49$169,020
MultaqDronedarone Hcl24$42,245
XareltoRivaroxaban48$37,228
EntrestoSacubitril/Valsartan40$36,715
Dofetilide114$27,755
Ranolazine ErRanolazine73$7,962
Flecainide Acetate84$4,012
Mexiletine Hcl29$3,017
ClopidogrelClopidogrel Bisulfate359$2,793
Midodrine Hcl21$2,117
Propafenone Hcl ErPropafenone Hcl19$1,671
Propafenone Hcl32$1,511
Fludrocortisone Acetate38$1,413
Metoprolol Succinate128$1,333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$202$291,988306 claims
Sanofi-aventis U.S. LLCMultaq$84$42,24524 claims
Johnson & JohnsonXarelto$473$37,22848 claims
NovartisEntresto$122$36,71540 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Anderson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →